<DOC>
	<DOCNO>NCT00200681</DOCNO>
	<brief_summary>This open-label , multi-centre , randomised Phase III study , look series 480 patient age 65 newly diagnose multiple myeloma ( MM ) previously treat . They receive VAD Velcade®/dexamethasone combination induction treatment plus/minus ( ± ) dexamethasone/cyclophosphamide/etoposide/cisplatin ( DCEP ) follow autograft first-line therapy , investigator try compare complete remission ( CR ) rate ( negative positive immunofixation ) end induction treatment .</brief_summary>
	<brief_title>IFM 2005-01 : Velcade/Dexamethasone Versus Vincristine/Adriamycin ( Doxorubicin ) /Dexamethasone ( VAD ) Treatment Patients With Multiple Myeloma</brief_title>
	<detailed_description>After write informed consent obtain eligibility verify , patient randomise 4 treatment arm : A1 VAD ( 4 cycle ) ; A2 VAD ( 4 cycle ) follow DCEP ( 2 cycle ) ; B1 Velcade® + dexamethasone ( 4 cycle ) ; B2 Velcade® + dexamethasone ( 4 cycle ) follow DCEP ( 2 cycle ) A1 , A2 , B1 , B2 + autograft . Randomisation stratify basis initial b2 microglobulin level ( &gt; &lt; 3 mg/l ) presence chromosome 13 abnormality identify FISH analysis . VAD : Vincristine/Adriamycin/Dexamethasone ; DCEP : Dexamethasone/Cyclophosphamide/ Etoposide/Cisplatin .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Recently diagnose MM accord criterion South West Oncology Group ( SWOG ) Not previously treat , apart local radiotherapy , case threaten incapacitate lesion , and/or 4day block dexamethasone ( 40 mg/mL ) emergency Stage II III disease accord Durie Salmon classification Stage I disease symptomatic bone lesion &lt; 65 year age Ability give sign informed consent Secretion measurable monoclonal spike ( &gt; 10 g/l serum 0.2 g/24h urine ) Negative pregnancy test inclusion ( necessary ) Absence active infection . In case infection , appropriate antibiotic therapy must administer patient must apyretic 48 hour start treatment VAD Velcade®/dexamethasone ECOG performance status &gt; 2 History cancer ( basal cell carcinoma carcinoma cervix situ ) Life expectancy &lt; 2 month Confirmed amyloidosis Positive HIV serology Serious psychiatric item history Renal failure require dialysis Uncontrolled diabetes , contraindicate use corticosteroid Peripheral neuropathy National Cancer Institute ( NCI ) grade &gt; 2 ( Annex 5 ) Clinical sign heart failure coronary heart disease Bilirubin &gt; 3 x normal Transaminases gammaglutamyl transpeptidase ( GT ) &gt; 4 x normal Platelets &lt; 50 x 10^9/l 15 day prior inclusion Neutrophils &lt; 0.75 x 10^9/l 15 day prior inclusion Use investigational medicinal product 30 day prior inclusion Known hypersensitivity bortezomib , boron mannitol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>Secretory Multiple Myeloma</keyword>
	<keyword>First line treatment</keyword>
	<keyword>Velcade®</keyword>
	<keyword>autograft</keyword>
	<keyword>Newly diagnose secretory Multiple Myeloma ( MM )</keyword>
</DOC>